Gilead’s remdesivir helped healthier Covid-19 patients:Study
Team Udayavani, May 24, 2020, 12:59 PM IST
As per a recent study, Gilead’s remdesivir, the first medicine cleared for the treatment of Covid-19, mainly benefited healthier patients who weren’t dependent on ventilators
According to the report in the New England Journal of Medicine, the drug helped patients infected with the coronavirus heal faster, allowing them to return home after about 11 days, compared to 15 days for those who were treated with a placebo.
Researchers said, “Given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient. Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19”
Researchers also said that the only group to do significantly better on remdesivir were those who were sick enough to need supplemental oxygen, but who weren’t yet on a ventilator or a heart-lung bypass machine.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Key to past: Indore man collects 570 typewriters from across the world
Kambala: Tradition and modernity in coastal Karnataka
Dairy farmers in K’taka border areas selling milk to Kerala for higher price!
Kadaba: ‘Notion that only English-medium education leads to success is misleading’
Udupi: ‘Team Taulava’ takes charge to preserve endangered ancient monuments
MUST WATCH
Latest Additions
Dedicated freight corridor is ‘jewel of Indian Railways’: Vaishnaw
ED seizes Rs 8.8 crore from corporate office of ‘lottery king’ Santiago Martin
Delhi CM Atishi announces staggered timings for government offices to tackle traffic congestion
India to clock 7.2 pc growth in 2024, RBI to hold interest rates steady this year: Moody’s
Govt that does encounters doesn’t trust Constitution: Akhilesh Yadav
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.